TD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating

The probe steadfast raised its Q1 EPS estimation from $5.05 to $5.21 to lucifer the company’s guidance. Thermo Fisher Scientific Inc. (NYSE:TMO) expects 1% integrated maturation for the archetypal quarter. This guidance includes a 1.8% antagonistic interaction owed to 1 little time and a planned lawsuit shutdown.

The steadfast besides noted that the company’s absorption expressed optimism astatine TD Cowen’s March league regarding request trends for Q1 and 2026. TD Cowen pointed retired that operating margins successful Q1 are expected to autumn compared to the aforesaid play past year. The probe steadfast added that Q1 volition correspond the debased constituent for EPS growth.

TD Cowen sees pharma spot and imaginable preclinical betterment arsenic cardinal factors that volition enactment integrated maturation acceleration successful the 2nd fractional of the year.

Thermo Fisher Scientific Inc. (NYSE:TMO) is simply a starring beingness subject and objective probe institution that supplies analytical instruments, objective improvement solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services.

While we admit the imaginable of TMO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Performing AI Stocks to Buy and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None. Follow Insider Monkey connected Google News.